Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467212 | 1.00 | HSD11B1 (0.42) | HSD11B1ABL1RIN1TDP1NPC1 | |
| SCHEMBL3644735 | 0.98 | HSD11B1 (0.42) | HSD11B1ABL1RIN1TDP1NPC1 | |
| SCHEMBL31441137 | 0.98 | HSD11B1 (0.42) | HSD11B1ABL1RIN1TDP1NPC1 | |
| SCHEMBL15822378 | 0.98 | HSD11B1 (0.42) | HSD11B1ABL1RIN1TDP1NPC1 | |
| SCHEMBL625012 | 0.96 | HSD11B1 (0.42) | HSD11B1ABL1RIN1TDP1NPC1 | |
| SCHEMBL30373977 | 0.96 | HSD11B1 (0.42) | HSD11B1ABL1RIN1TDP1NPC1 | |
| SCHEMBL20558279 | 0.93 | HSD11B1 (0.44) | HSD11B1ABL1RIN1TDP1ALDH1A1 | |
| SCHEMBL14542590 | 0.85 | HSD11B1 (0.40) | HSD11B1ALDH1A1TNFOPRM1OPRD1 | |
| SCHEMBL19785446 | 0.85 | HSD11B1 (0.40) | HSD11B1MEN1KMT2ATNFOPRM1 | |
| SCHEMBL3406168 | 0.83 | HSD11B1 (0.42) | HSD11B1ALDH1A1MEN1KMT2ATNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435051-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON, INC. (KR) | 2025-10-07 | — | — | US | disclosed |
| US-20240360092-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | VIVOZON INC. (KR) | 2024-10-31 | — | — | US | disclosed |
| US-12060339-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON INC. (KR) | 2024-08-13 | — | — | US | disclosed |
| EP-4190770-A1 | DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF | Vivozon, Inc. (KR) | 2023-06-07 | — | — | EP | disclosed |
| EP-4190770-A1 | DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF | Vivozon, Inc. (KR) | 2023-06-07 | — | — | EP | disclosed |
| CN-116234552-A | Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof | (株)倍宝尊 | 2023-06-06 | — | — | CN | disclosed |
| US-20220274939-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | VIVOZON INC. (KR) | 2022-09-01 | — | — | US | disclosed |
| CN-113061098-B | Amide compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022025636-A1 | DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF | 주식회사 비보존 | 2022-02-03 | — | — | WO | disclosed |
| CN-113061098-A | Amide compound and derivative thereof, preparation method, pharmaceutical composition and application | 中国药科大学 | 2021-07-02 | — | — | CN | disclosed |
| WO-2014057078-A1 | BENZAMIDES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2006033844-A9 | 4-ARYLSPIROCYCLOALKYL-2-AMINOPYRIMIDINE CARBOXAMIDE KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2006033844-A9 | 4-ARYLSPIROCYCLOALKYL-2-AMINOPYRIMIDINE CARBOXAMIDE KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1789397-A2 | 4-ARYLSPIROCYCLOALKYL-2-AMINOPYRIMIDINE CARBOXAMIDE KCNQ POTASSIUM CHANNEL MODULATORS | Bristol-Myers Squibb Company (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7091202-B2 | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| WO-2006033844-A2 | 4-ARYLSPIROCYCLOALKYL-2-AMINOPYRIMIDINE CARBOXAMIDE KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063790-A1 | 4-Arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435051-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | GRM5, HTR5A, HTR2A | HSD11B1 4218/4885ABL1 4061/4885RIN1 2489/4885 |
| US-20240360092-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | GRM5, HTR5A, HTR2A | HSD11B1 4218/4885ABL1 4061/4885RIN1 2489/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | HSD11B1 847/4885ABL1 817/4885RIN1 766/4885 |
| US-12060339-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | GRM5, HTR5A, HTR2A | HSD11B1 4218/4885ABL1 4061/4885RIN1 2489/4885 |
| US-20060063790-A1 | 4-Arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators | KCNQ2, KCNQ1, KCNQ4 | HSD11B1 4572/4885ABL1 3713/4885RIN1 3714/4885 |
| US-20220274939-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | GRM5, HTR5A, HTR2A | HSD11B1 4218/4885ABL1 4061/4885RIN1 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.